Paul Reider
Corporate Officer/Principal bij COHERUS BIOSCIENCES, INC.
Vermogen: 194 252 $ op 31-03-2024
Profiel
Paul Reider is a member of the Clinical Advisory Board at Tetraphase Pharmaceuticals, Inc. He is also the Chief Commercial Officer at Coherus BioSciences, Inc. starting in 2022.
Previously, he worked as the Vice President of Sales & Strategic Accounts at Puma Biotechnology, Inc. from 2019 to 2021.
He also held a position as the General Manager at Ipsen Biopharmaceuticals Canada, Inc. Mr. Reider completed his undergraduate degree and MBA at Bowling Green State University.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 20-01-2024 | 81 277 ( 0.07% ) | 194 252 $ | 31-03-2024 |
Actieve functies van Paul Reider
| Bedrijven | Functie | Begin |
|---|---|---|
| COHERUS BIOSCIENCES, INC. | Corporate Officer/Principal | 01-01-2021 |
| TETRAPHASE PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Eerdere bekende functies van Paul Reider
| Bedrijven | Functie | Einde |
|---|---|---|
| PUMA BIOTECHNOLOGY, INC. | Sales & Marketing | 01-01-2021 |
| Ipsen Biopharmaceuticals Canada, Inc. | Corporate Officer/Principal | - |
Opleiding van Paul Reider
| Bowling Green State University | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| PUMA BIOTECHNOLOGY, INC. | Health Technology |
| COHERUS BIOSCIENCES, INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Tetraphase Pharmaceuticals, Inc.
 Tetraphase Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetraphase Pharmaceuticals, Inc. is engaged in the development and production of novel tetracyclines for serious and life-threatening bacterial infections. It also develops eravacycline, a synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Waltham, MA. | Health Technology |
| Ipsen Biopharmaceuticals Canada, Inc. |
